|
| What are this week’s market risks or opportunities? |
|
|
| This week, one headline repriced an entire industry. |
|
| Moderna announced positive late-stage trial results for its mRNA cancer therapy, developed with Merck to treat melanoma, and the stock rocketed almost +177% in a single session. |
|
| The excitement spilled everywhere: healthcare was the strongest sector of the week, and biotech names climbed in sympathy from the U.S. to Europe to Korea. |
|
| That is how breakthroughs work: one result, and the whole neighborhood gets marked up overnight. |
|
| It feels thrilling, and it also feels like something you already missed. |
|
| But a one-day moonshot on trial data is not a trade you can repeat. The more useful question is what keeps climbing after the headline fades. |
|
|
|
|
|
|
| Which trades should I consider? |
|
|
| Away from the headlines, our ProPicks AI Healthcare Heroes strategy has been loading up on the sector's long-term winners, and they are not vaccine lottery tickets. |
|
| They are actual, reliable earnings compounders. Just to name a couple recent examples:
|
| Our AI picked each one for accelerating profit growth, and quarter after quarter of delivery is what keeps them climbing. |
|
| That is the gap between chasing a headline and building a repeatable edge, and it is exactly what our AI models are here for. |
|
| Moderna's breakthrough might have (rightly so) grabbed the spotlight, but quietly compounding earnings are still doing the real work in winning portfolios. |
|
|
|
|
|
|
| Should I consider this trade? |
|
|
| One name captures the whole idea: Bausch Health (BHC), picked by our AI due to its durable fundamentals. |
|
| With Q2 revenue of $2.85 billion, a 13th consecutive quarter of top and bottom line growth, and earnings of $1.26 per share against $1.01 expected, it just kept quietly executing. |
|
| The market is finally catching on: the stock is up more than +47% in the past month. |
|
But despite the rally, it still trades below fair value, according to our models:
- Fair Value: Undervalued. Fair Price $9.48, +37.66% upside
- Financial Health: Great
- Technical read: Strong Buy
|
| A consistent grower still trading below fair value rarely stays cheap for long, and Bausch is not the only name our AI has flagged. |
|
|
|
|
|
|
| Data correct to 20.08.2026. |
|
Posts
